‘HIV-ending’ drug could be made for just $25 per patient a year, say researchers
As regulator prepares to approve Lenacapavir in the US, campaigners are urging the manufacturer, Gilead, to make it ‘available and affordable for all who need it’
Archived version: https://archive.is/newest/https://www.theguardian.com/society/2025/jun/17/hiv-ending-drug-lenacapavir-manufacture-cost-per-patient-gilead
Disclaimer: The article linked is from a single source with a single perspective. Make sure to cross-check information against multiple sources to get a comprehensive view on the situation.
https://www.theguardian.com/society/2025/jun/17/hiv-ending-drug-lenacapavir-manufacture-cost-per-patient-gileadOpen linkView original on lemmy.zip157
Comments6
Made for cheap, sold for thousands. Sounds like epi-pens
My last Jaxt adrenaline injector was 56 euros. An EpiPen would have been 2 whole euros extra.
Actual price they will charge: One Million Dollars
"Oh, we can't do that. We have to make back R&D costs and turn a nice profit for like a decade before other companies are allowed to produce a generic version. We're literally going to capitalize on human suffering. Suck it."
Narrator: It wasn't.
We'll just take this to India annnnd it's $15